NASDAQ:DCPH - Deciphera Pharmaceuticals Stock Price, News, & Analysis

$23.06
+1.62 (+7.56 %)
(As of 06/18/2019 03:06 AM ET)
Today's Range
$21.93
Now: $23.06
$23.48
50-Day Range
$21.23
MA: $23.05
$24.67
52-Week Range
$18.55
Now: $23.06
$45.61
Volume354,900 shs
Average Volume189,063 shs
Market Capitalization$880.64 million
P/E RatioN/A
Dividend YieldN/A
Beta2.65
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DCPH
CUSIPN/A
Phone781-209-6400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$7.43 per share

Profitability

Net Income$-99,850,000.00

Miscellaneous

Employees112
Market Cap$880.64 million
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable

Receive DCPH News and Ratings via Email

Sign-up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.

Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) announced its quarterly earnings data on Thursday, May, 9th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by $0.41. View Deciphera Pharmaceuticals' Earnings History.

When is Deciphera Pharmaceuticals' next earnings date?

Deciphera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Deciphera Pharmaceuticals.

What price target have analysts set for DCPH?

9 Wall Street analysts have issued 1-year target prices for Deciphera Pharmaceuticals' stock. Their predictions range from $20.00 to $65.00. On average, they anticipate Deciphera Pharmaceuticals' stock price to reach $46.2857 in the next year. This suggests a possible upside of 100.7% from the stock's current price. View Analyst Price Targets for Deciphera Pharmaceuticals.

What is the consensus analysts' recommendation for Deciphera Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Deciphera Pharmaceuticals.

What are Wall Street analysts saying about Deciphera Pharmaceuticals stock?

Here are some recent quotes from research analysts about Deciphera Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States. " (2/12/2019)
  • 2. Cantor Fitzgerald analysts commented, "We are Overweight on DCPH with a 12-month price target of $53 based on lead asset DCC-2618 (in 4L GIST). Compelling safety and clinical activity data were presented at ASCO ‘18, which we view positively when compared to SOC sunitinib in earlier 2L patients. We believe the recent data de-risks the P3 program for 4L pts, reads on the broad potential in GIST & other malignancies, and reinforces our conviction in the platform/clinical strategy. In addition, emerging ‘2618 data in 2L/3L pts suggest superiority to SOC in terms of response rate & durability, a clinical profile that could drive ~$2.7B in peak sales." (12/20/2018)
  • 3. Canaccord Genuity analysts commented, "We continue to expect DCC-2618 durability in GIST cohorts will be a key focus for investors. The Phase 1 is assessing DCC-2618 in 3 separate indications, GIST (cohorts for 2L, 4L, and 5L), advanced systemic mastocytosis (aSM), and glioma/ glioblastoma multiforme (GBM). In November, Deciphera initiated pivotal Invictus trial in 4L GIST and plans to start second Ph3 Intrigue 2L GIST trial by year-end. DCC-2618 has US and EU orphan designation." (8/13/2018)

Has Deciphera Pharmaceuticals been receiving favorable news coverage?

Media coverage about DCPH stock has trended positive on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Deciphera Pharmaceuticals earned a news sentiment score of 2.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Deciphera Pharmaceuticals.

Who are some of Deciphera Pharmaceuticals' key competitors?

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Who are Deciphera Pharmaceuticals' key executives?

Deciphera Pharmaceuticals' management team includes the folowing people:
  • Dr. Daniel L. Flynn, Exec. VP, Chief Scientific Officer & Founder (Age 64)
  • Mr. Christopher J. Morl, Chief Bus. Officer (Age 60)
  • Countess Steven L. Hoerter, Pres, CEO & Director (Age 48)
  • Mr. Thomas Patrick Kelly J.D., Exec. VP, CFO & Treasurer (Age 48)
  • Dr. Stephen B. Ruddy Ph.D., Chief Technical Officer (Age 55)

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Who are Deciphera Pharmaceuticals' major shareholders?

Deciphera Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Redmile Group LLC (4.26%), Janus Henderson Group PLC (1.73%), Emerald Advisers LLC (1.06%), Emerald Mutual Fund Advisers Trust (0.95%), Marshall Wace North America L.P. (0.15%) and CIBC Asset Management Inc (0.11%). Company insiders that own Deciphera Pharmaceuticals stock include Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, New Leaf Venture Management Ii and Thomas Patrick Kelly. View Institutional Ownership Trends for Deciphera Pharmaceuticals.

Which major investors are selling Deciphera Pharmaceuticals stock?

DCPH stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Janus Henderson Group PLC, Redmile Group LLC and Marshall Wace LLP. Company insiders that have sold Deciphera Pharmaceuticals company stock in the last year include Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor and Thomas Patrick Kelly. View Insider Buying and Selling for Deciphera Pharmaceuticals.

Which major investors are buying Deciphera Pharmaceuticals stock?

DCPH stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., CIBC Asset Management Inc and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Deciphera Pharmaceuticals.

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Deciphera Pharmaceuticals' stock price today?

One share of DCPH stock can currently be purchased for approximately $23.06.

How big of a company is Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals has a market capitalization of $880.64 million. The company earns $-99,850,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis. Deciphera Pharmaceuticals employs 112 workers across the globe.View Additional Information About Deciphera Pharmaceuticals.

What is Deciphera Pharmaceuticals' official website?

The official website for Deciphera Pharmaceuticals is http://www.deciphera.com/.

How can I contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals' mailing address is 500 Totten Pond Road, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]


MarketBeat Community Rating for Deciphera Pharmaceuticals (NASDAQ DCPH)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  187 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  373
MarketBeat's community ratings are surveys of what our community members think about Deciphera Pharmaceuticals and other stocks. Vote "Outperform" if you believe DCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel